Wells Fargo & Company Can Fite Bio Pharma Ltd. Transaction History

Wells Fargo & Company

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$0.83 - $1.24 $1,245 - $1,860	-1,500 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$1.8 - $2.92 $2,700 - $4,380	1,500 New	1,500 $4,000

1.1K

Ticker CANF
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,191,500
Market Cap $57.1M
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinic...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.